SHANGHAI, Dec. 16, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with an integrated industry chain, announced that it has completed the first commercial shipment of ...

Amneal Pharmaceuticals has just seen its fair value estimate nudged to US$14.00 from US$13.80, a small but meaningful reset that ties directly to how the latest quarterly numbers stack up against ...

Dec. 3 (UPI) --Privately owned, standalone infusion centers are increasingly providing a comfortable and convenient alternative to hospitals and doctors' offices for people on prescribed medications ...

From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of ...

Novo Nordisk carries a Zacks Rank #5 (Strong Sell), whereas Amgen carries a Zacks Rank #3 (Hold) at present, which makes AMGN ...

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration. After a cautious ...

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027BRIDGEWATER, ...

Sandoz has launched Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg) across Europe, among the first denosumab biosimilars approved for all Xgeva® and Prolia® indications, targeting ...

IT’S easy to brush off your broken nails, especially at this time of the year. All the washing up over Christmas, the cold ...